Spain Invests €126.9M in Groundbreaking EU Health Innovation Project Med4Cure

The Ministry of Science, Innovation and Universities in Spain, through the Center for Technological Development and Innovation ( CDTI ), has published the final resolution for the financing of Spanish companies participating in the Important Project of Common European Interest in Health (IPCEI) Med4Cure, having approved the granting of subsidies for a total amount of 126.9 million euros.

This action is part of Spain’s commitment to strengthening the resilience of the healthcare sector, promoting sustainable innovation, and placing national companies at the forefront of European pharmaceutical research and production.

The Important European Project of Common European Interest in Health, known as IPCEI Med4Cure, will deliver innovations against diseases for which there are no effective means of prevention or treatment, while also increasing the European Union ‘s prevention efforts against emerging health threats.

The projects focus on research, innovation, and industrial deployment of medical devices, as well as innovative production processes in the pharmaceutical sector in Spain

This is the first initiative of its kind in the healthcare sector in Spain, endorsed by the European Commission in May 2024. It aims to address strategic challenges: from the development of advanced therapies for rare diseases and antimicrobial resistance to the adoption of more sustainable and efficient production processes.

Spain joined five Member States — Belgium, Slovakia, France, Hungary, Italy —, notifying the participation of 13 companies in 14 projects, of which one acts as a direct participant (Sylentis) and five as associates: Laboratorios Farmacéuticos Rovi , SA, Laboratorios Reig Jofre , SA, Medichem, SA, Minoryx Therapeutics, SL and Oryzon Genomics, SA.

The direct grants published fund R&D activities for the six participants, as well as the first industrial deployment for the direct participant (Sylentis).

Spain now at the forefront of research

Sylentis will receive €21 million for the rehabilitation and GMP certification of its oligonucleotide plant in Getafe, incorporating BREEAM standards and reducing Process Mass Intensity (PMI), while advancing the preclinical phase of new therapeutic candidates.

Rovi Pharmaceutical Laboratories has received €36.3 million for the LAISOLID project, which focuses on aseptic filling technology for polymer matrices for drug-eluting implants and biological products.

Reig Jofre Laboratories will receive €13.1 million in funding for the EMINTECH project, which integrates gene therapies, CAR-T cells, and bacteriophages to combat antimicrobial resistance and rare diseases.

Medichem receives 16.2 million to optimize manufacturing processes for APIs and specialized formulations in areas such as cystic fibrosis.

Minoryx Therapeutics secures $26.8 million for LERI4CNS, which will clinically validate leriglitazone for leukodystrophies and other rare CNS diseases.

Finally, Oryzon Genomicas will receive 13.2 million euros in funding for the development of VANDAM, a program aimed at personalized epigenetic therapies for neurodevelopmental disorders and rare tumors.

__

(Featured image by Jorge Fernández Salas via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us